Center for Cardiovascular Research/Institute of Pharmacology, Charité-University Medicine Berlin, Berlin, Germany.
Hypertens Res. 2010 Feb;33(2):98-104. doi: 10.1038/hr.2009.206. Epub 2009 Dec 11.
The (pro)renin receptor ((P)RR) not only represents a novel component of the renin-angiotensin system but is also a promising novel drug target because of its crucial involvement in the pathogenesis of renal and cardiac end-organ damage. This review discusses the signal transduction of the (P)RR with its adapter protein promyelocytic zinc-finger protein, the impact of this receptor, especially on cardiovascular disease, and its putative interaction with renin inhibitors such as aliskiren. Furthermore, the increasing complexity regarding the cellular function of the (P)RR is addressed, which arises by the intimate link with proton pumps and the phosphatase PRL-1, as well as by the presence of different subcellular localizations and of a soluble isoform of the (P)RR. Finally, the rationale and strategy for the development of small-molecule antagonists of the (P)RR, called renin/prorenin receptor blockers, are presented.
(前)肾素受体 ((P)RR) 不仅是肾素-血管紧张素系统的一个新组成部分,而且还是一个有前途的新型药物靶点,因为它在肾脏和心脏靶器官损伤的发病机制中起着至关重要的作用。本文讨论了 (P)RR 与其衔接蛋白早幼粒细胞白血病锌指蛋白的信号转导,该受体特别是对心血管疾病的影响,以及它与阿利克仑等肾素抑制剂的潜在相互作用。此外,还探讨了 (P)RR 的细胞功能日益复杂化的问题,这是由于它与质子泵和磷酸酶 PRL-1 的密切联系,以及不同的亚细胞定位和 (P)RR 的可溶性同工型的存在所致。最后,还介绍了(前)肾素受体小分子拮抗剂的开发原理和策略,即肾素/(前)肾素受体阻滞剂。